The Pharmaceutical Journal
Vol 274 No 7343 p382
2 April 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Buprenorphine guidance

Guidance relating to the crushing of buprenorphine sublingual tablets (Subutex) has been issued by the Royal Pharmaceutical Society (see p401). In parallel with the guidance, the National Pharmaceutical Association has agreed to provide indemnity cover to members who crush buprenorphine sublingual tablets under an agreed protocol.

Further details of the protocol are available on NPAnet, the NPA’s member-only intranet.